Publications

Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.

* denotes publications from the CTD2 initiative that are results of intra-Network collaborations

 

CTD²
September 04, 2018
Scientific Reports

High-throughput functional siRNA screening in ovarian cancer cell lines identified that tyrosine kinase with immunoglobulin-like and EGF-like domains 1, TIE-1 confers resistance to cisplatin and could be a potential therapeutic target for platinum resistant ovarian cancer. 

CTD²
September 01, 2018
Leukemia

Studies conducted by CTD2 scientists at Oregon Health and Science University have shown that combined inhibition of JAK1/2 and BCL2 as a potential therapeutic option for acute myeloid leukemia (AML) patients.

CTD²
August 13, 2018
Nature Cell Biology

CTD2 researchers at UCSF showed that SHP2, a non-receptor protein tyrosine phosphatase, could be a potential molecular target in cancers driven by oncogenic mutants of RAS/MAPK pathway.

CTD²
August 13, 2018
Journal of Clinical Pathology

Review on the role of CDK12 as a clinical biomarker and as a potential therapeutic target for cancer therapy.

CTD²
August 08, 2018
Trends in Cancer

A review article on using the patient-derived cancer models for the identification of targets to overcome roadblocks of precision oncology.

Pages

CSVXML